Oncology

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed positive data in ccRCC that he believes should excite the solid tumor field as a whole.

Review top news and interview highlights from the week ending May 12, 2023.

The neoantigen-specific TCR therapy is the first to enter clinical trials out of a collaboration with Genentech.

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s manufacturing-focused approach to overcoming the challenges of the solid tumor microenvironment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The cell therapy field applications staff scientist at ThermoFisher discussed advantages of the company’s DynaCellect system.

SynKIR-110 was also granted fast track designation by the FDA in April 2023.

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s research with a newly developed assay method that was presented at AACR’s 2023 conference.

Review top news and interview highlights from the week ending May 5, 2023.

The head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.

The decision, which aligns with its indication in the US, was based on efficacy and safety results from Bristol Myers Squibb’s TRANSFORM clinical trial in forms of large B-cell lymphoma.

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Bristol Myers Squibb noted that in addition to meeting the ORR end point, both trials also met a key secondary CR rate end point.

The chief medical officer of Trisalus Life Sciences discussed the company’s PEDD system and SD-101.

Kiromic BioPharma expects to initiate a phase 1 clinical trial for Deltacel within Q2 2023.

The cofounder and chief scientific officer of Xcell Biosciences discussed the limitations of the methods currently used for modeling in preclinical cell therapy research for solid tumors.

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

The vice president of business development and alliances at Prescient Therapeutics discussed the mechanism of the OmniCAR technology.

Review top news and interview highlights from the week ending April 28, 2023.

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate director of research at Lyell Immunopharma discussed the company’s programs and newest technologies aimed at solid tumors.

The instructor at Stanford Institutes of Medicine discussed the key takeaways of her research into the factors that affect CAR-T expansion.

The research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.